Navigation Links
Start of Phase II Study for Intranasal, Seasonal Influenza Vaccine deltaFLU
Date:1/13/2010

VIENNA, Austria, January 13 /PRNewswire/ --

- By Starting the Phase II Study for deltaFLU, AVIR Green Hills AG has Accomplished yet Another Milestone in the Development of this Novel Influenza Vaccine. Completion of this Clinical Phase II Study is Envisaged for Spring 2010

- The Positive Results Obtained in the Previous Clinical Phase I Study will be Published in the Renowned "Journal of Infectious Diseases" on 15 January 2010

AVIR Green Hills Biotechnology, the innovative biotech company based in Vienna, has started the New Year by embarking on the first clinical phase II study for the seasonal vaccine deltaFLU. The study will be carried out at the Medical University of Vienna. With this step, AVIR Green Hills has set yet another important milestone in the development of effective and modern influenza vaccines.

Start of clinical phase II study

In a randomized double blind study, the vaccine will be administered intranasally to 48 volunteers.

"In double blind studies, neither the administering physician (and/or the commissioning party) nor the volunteers know who gets the placebo. Moreover, none of them knows which sprays contain the tested vaccine and which contain the placebo," explains Franz Groiss, who is in charge of managing clinical studies at AVIR Green Hills Biotechnology. The study will be headed by Volker Wacheck and carried out at the Department of Clinical Pharmacology at the Vienna General Hospital.

Aim of phase II study

The aim of the phase II study is to optimize the vaccine dose and to substantiate the efficiency of the vaccine and its ability to trigger an immune response.


'/>"/>

SOURCE AVIR Green Hills Biotechnology AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD)
2. JumpStart Invests in Checkpoint Surgical
3. Prodromal Symptoms Warn of Hereditary Angioedema Attacks, Give Patients Time to Start Therapy and Decrease Morbidity
4. Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
5. Dong-A PharmTech Co., Ltd. Announces Start of Phase III Trials for Udenafil, Its New Erectile Dysfunction Drug Under Development
6. AMT Starts Development LPLChip(TM) With Progenika
7. American Association for Homecare Proposes Strong Anti-Fraud Measures in Medicare, Applauds HHS Testimony Today That Pledges to "Stop Fraud Before it Starts"
8. Patients who Participated in Pleio GoodStart(TM) Refilled 30% Sooner and 40% More, Averaging 2 Additional Rx Refills per Patient
9. R-Tech Ueno Starts Early Phase II Clinical Trial for RK-023
10. Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Melanoma Cancer Clinical Trial
11. Cytopias CYT387 Receives FDA Clearance to Start US Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... According to the new ... therapy, Hydrotherapy), Accessories (Posture Mirror, Exercise Ball), Applications (Pediatric, ... Global Forecast to 2019" published by MarketsandMarkets, the global ... Million by 2019 from $14,240.0 Million in 2014, ... 2019. Browse 74 market data tables ...
(Date:9/19/2014)... Research and Markets has announced the ... Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023" ... this report, the human microbiome market is segmented by application, ... is expected to be valued as $294 million in 2019 ... within the forecast period of 2019-2023. The market is driven ...
(Date:9/19/2014)... Mich. , Sept. 19, 2014  Diplomat, the ... of David Dreyer to the Board of ... independent director and will also serve as chair of ... almost 30 years of accounting, financial, compliance and operating ... Mr. Dreyer has served as chief financial officer, chief ...
Breaking Medicine Technology:Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 4Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 2Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 3David Dreyer Appointed to Diplomat Board of Directors 2
(Date:9/21/2014)... Dallas, Texas (PRWEB) September 22, 2014 ... over the past decade, as it has become ... short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids ... has also been facing increasing generic competition. However, ... and once-daily ICS and ICS/LABA therapies delivered by ...
(Date:9/21/2014)... 21, 2014 "I want to help ... back but haven’t the money for chiropractors," said an ... have such a product for myself." , The Stretch ... stretch the thigh muscles and align the spine properly. ... relieves discomfort of pinched nerves. Compact and easy to ...
(Date:9/21/2014)... women starting college understand the benefits of a healthy ... they aren,t confident they can follow through on these ... The study involved 268 female college freshmen enrolled ... Eating Right program. The students answered food-related questions such ... were very busy with school work, were very hungry ...
(Date:9/21/2014)... (PRWEB) September 21, 2014 Originally ... in 1996, GSK’s Flovent (fluticasone propionate) is a ... is used for the maintenance treatment of asthma ... available in two formulations, Diskus and HFA, which ... respectively. Flovent’s active ingredient, fluticasone propionate, can bind ...
(Date:9/21/2014)... 21, 2014 High in the rugged ... disabled and able-bodied athletes rafted the Colorado River, rode ... course in pursuit of outdoor adventure. At the September ... World T.E.A.M. Sports, disabilities proved to be no more ... the three stage event. , Each participating team of ...
Breaking Medicine News(10 mins):Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4Health News: College Women Can Use Food Strategies, Study Finds 2Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4Health News:Disabled Athletes Excel at World T.E.A.M. Sports’ Adventure Team Challenge 2Health News:Disabled Athletes Excel at World T.E.A.M. Sports’ Adventure Team Challenge 3
... in Federal Funds Awarded to Reconstruct Devastating,Injuries;, ... HEIGHTS, Ill., April 17 Members of,the American ... pivotal role,over the next five years developing groundbreaking ... Iraq and Afghanistan. The U.S.,Department of Defense (DoD) ...
... for cosmetic purposes might also improve wound healing and ... scarred during combat. Dr. Adam Katz, plastic surgeon and ... conduct research in this area under the Armed Forces ... announce the formation of AFIRM, which has received more ...
... CARLSBAD, Calif., April 17 The National Center ... resource for autism research, education and family support,services ... Families are,flocking to NCARE resulting from the announcement ... is that families desperately need centralized,autism resources., ...
... With Information and,Best Practices Related to Upcoming ... April 17 The new Centers for,Medicare ... eliminate or,reduce payments for three hospital-acquired infections ... conference for healthcare executives and professionals,sponsored by ...
... The National,Association of Specialty Health Organizations ... Innovation Award. The recipient of the award,will ... through,innovative programs and practices., (Logo: ... for the specialty health industry, we felt ...
... April 17 MSA (NYSE: MSA ), the,global ... that protect people,s health and safety, announced today that ... live via the,Internet on Thursday, May 1, 2008 at ... Investors and interested parties will have the opportunity ...
Cached Medicine News:Health News:Plastic Surgeons Play Pivotal Role in War Injury Research 2Health News:Plastic Surgeons Play Pivotal Role in War Injury Research 3Health News:UVA Health System part of Armed Forces multi-million dollar effort to help soldiers 2Health News:California's First Non-profit Center for Autism Research, Education and Family Services 2Health News:APIC Conference to Address New CMS Regulations 2Health News:The National Association of Specialty Health Organizations to Recognize Excellence in Technology Education With Industry Award 2Health News:MSA Schedules First Quarter Earnings Webcast 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: